NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 130 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.07 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $229 | -72.4% | 213,676 | -33.4% | 0.02% | -75.9% |
| Q2 2023 | $831 | -52.6% | 320,912 | -25.3% | 0.08% | -52.0% |
| Q1 2023 | $1,752 | +170.0% | 429,469 | +232.2% | 0.17% | +113.6% |
| Q4 2022 | $649 | -99.6% | 129,279 | +1069.0% | 0.08% | +326.3% |
| Q3 2022 | $145,000 | -89.8% | 11,059 | -76.4% | 0.02% | -91.8% |
| Q4 2020 | $1,421,000 | – | 46,908 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |